Delivery Order SPE2DR25D6028-SPE2DR26FATTV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,116.80 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 6, 2026, with an ultimate completion date of January 7, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $10,692.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 2, 2026, with an ultimate completion date of January 5, 2026. This non-set-aside award was performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion...
- The Defense Logistics Agency awarded a delivery order valued at $108,228.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's headquarters in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $6,558.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 8, 2025, with completion targeted for December 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a $54.3K delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania and an ultimate completion date of January 7, 2026. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.9M vehicle valued...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $46,395.18 for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed price contract. This non-competitive delivery order, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $17,740.56 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 9, 2026, with a completion date of January 12, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp on May 30, 2025, for RINVOQ ER 15 mg tablets (30-count units), with final delivery scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (SPE2DX)...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FATTVDelivery Order
The Defense Logistics Agency awarded a $19,675.26 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of RINVOQ ER 15mg tablets (30-count bottles). This is a firm fixed-price, non-set-aside contract with a completion date of January 14, 2026, and performance location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has demonstrated significant capability in federal medical procurement through its extensive portfolio of contract awards with the Defense Logistics Agency. The company supplies a wide range of pharmaceutical products across multiple therapeutic domains to support military treatment facilities and veteran healthcare programs. This delivery order for RINVOQ—a medication used in treating rheumatoid arthritis and other inflammatory conditions—reflects the company's role as a critical vendor in the federal medical supply chain and its ability to fulfill government pharmaceutical requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Loading... | ||||